PhaseBio Pharmaceuticals, Inc. Common Stock

PHAS

Market cap $3.5M

Delisted

PHAS was delisted on the 2nd of November, 2022.

#	Name	Holding	Trade Value	Shares Change	Change in Stake
1	1 Wellington Management Group Boston, Massachusetts	$10.4M	+$13.4M	+3,370,960	New
2	CAM 2 Cormorant Asset Management Boston, Massachusetts	$3.39M	+$4.35M	+1,097,926	New
3	RSCM 3 Rock Springs Capital Management Baltimore, Maryland	$2.58M	+$3.31M	+835,000	New
4	4 T. Rowe Price Associates Baltimore, Maryland	$2.01M	+$2.58M	+651,101	New
5	5 Alyeska Investment Group Chicago, Illinois	$592K	+$759K	+191,602	New
6	6 Vanguard Group Malvern, Pennsylvania	$544K	+$697K	+175,994	New
7	7 Millennium Management New York	$411K	+$527K	+133,022	New
8	8 Citigroup New York	$351K	+$450K	+113,605	New
9	DCM 9 DAFNA Capital Management Los Angeles, California	$309K	+$396K	+100,000	New
10	USAA 10 United Services Automobile Association San Antonio, Texas	$286K	+$367K	+92,614	New
11	LCM 11 Laurion Capital Management New York	$167K	+$214K	+54,072	New
12	12 TD Asset Management Toronto, Ontario, Canada	$96K	+$124K	+31,188	New
13	13 BlackRock New York	$79K	+$100K	+25,309	New
14	14 Deutsche Bank Frankfurt Am Main Ge, Germany	$6K	+$8.46K	+2,136	New
15	TRCT 15 Tower Research Capital (TRC) New York	$1K	+$1.62K	+408	New